Introduction: Guidelines recommend that patients with coronary artery disease (CAD) lower their low-density lipoprotein cholesterol (LDL-C) using maximally tolerated statin therapy to prevent recurrent events. Gaps in ambulatory LDL-C management (i.e., non-use of statins and elevated LDL-C) may reflect missed opportunities for secondary prevention and, if frequent, may warrant quality improvement interventions. Research question: What is the proportion of known CAD patients who do not take a statin or have elevated LDL-C before a recurrent event? Methods: We analyzed the prevalence of non-statin use and an LDL-C level ≥70 mg/dL in patients ≥18 years of age in the Get With The Guidelines-CAD registry who had known CAD and were hospitalized for a new myocardial infarction or unstable angina in 2023-2024. Data collection on statin use and LDL-C at the initial evaluation is optional in the registry. Information on the intensity of statin therapy is not available. Results: After excluding 17% of patients without data on prior statin use, 34,003 were included in the analysis (mean age 68 years; 71% male; 73% white). Overall, 31.6% of patients did not use a statin. No statin use was more prevalent among women than men, and less prevalent among Black vs White patients ( Table 1 ). LDL-C was not documented in 30.7% of patients. An LDL-C ≥70 mg/dL was more common in patients not taking vs those taking a statin (74.6% and 49.8%, respectively, multivariable-adjusted prevalence ratio 1.45; 95% CI 1.41, 1.48). Women were more likely than men to have an LDL-C level ≥70 mg/dL among those taking and not taking a statin, separately ( Table 2, Panel A). Black and Hispanic patients were more likely to have an LDL-C level ≥70 mg/dL compared to their white counterparts among those taking a statin, but there were no statistically significant differences by race/ethnicity among those not taking a statin ( Table 2, Panel B). Among patients discharged alive, 93.6% were prescribed a statin, and 85.2% were prescribed a high-intensity statin. Conclusion: The current results reveal that more than 30% of known CAD patients do not receive guideline-recommended statin therapy before a recurrent event. Furthermore, half of the patients taking a statin and three out of four of those not taking a statin have an LDL-C level above the guideline-recommended thresholds. Urgent, targeted quality improvement initiatives are needed to address these gaps and reduce the burden of recurrent CAD hospitalizations.
Colantonio et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: